Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 22;2(4):447-57.

Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis

Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis

Stephanie Norwood et al. Am J Transl Res. .

Abstract

Chronic inflammation is an important factor contributing to human carcinoma, and non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to have a preventive effect in the development of various types of carcinoma. However, NSAIDs also have adverse side effects including increased cardiovascular events, making them less than ideal for routine chemoprevention. Soluble epoxide hydrolase (sEH) is an enzyme that converts endogenous anti-inflammatory compounds, the epoxyeicosatrienoic acids (EETs), to the less anti-inflammatory dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH, by a highly selective and potent sEH inhibitor (sEHI), increases EETs leading to decreased inflammation. In our studies, administration of a sEHI in mouse colitis models led to decreased ulcer incidence and number of ulcers compared to controls, with no adverse side effects seen. In human tissue, sEH showed an increase in expression, as seen immunohistochemically, in ulcerative colitis (UC), UC-induced dysplasia, and UC-induced carcinoma. Thus, inhibition of sEH may be a novel biomarker and potential therapeutic target in inflammation and inflammation-induced carcinoma.

Keywords: Epoxyeicosatrienoic acids (EETs); cancer; carcinogenesis; dihydroxyeicosatrienoic acids (DHETs); inflammation; non-steroidal anti-inflammatory drugs (NSAIDs); soluble epoxide hydrolase (sEH); therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Epoxide hydrolase catalyzes diol formation by adding a water group to an epoxide.
Figure 2
Figure 2
Arachidonic acid metabolism and the physiologic effects of arachidonic acid metabolites. COX = cyclooxygenase, CYP2C = cytochrome p450 2C, CYP2J = cytochrome p450 2J, DHETs = dihydroxyeicosatrienoic acids, EETs = epoxyeicosatrienoic acids, LOX = lipoxygenase, sEH = soluble epoxide hydrolase.
Figure 3
Figure 3
Multiple pathways of inflammation inhibition through targeting sEH. COX-2 = cyclooxygenase-2, DHETs = dihydroxyeicosatrienoic acids, EETs = epoxyeicosatrienoic acids, iNOS = inducible nitric oxide synthase, 5-LOX = 5-lipoxygenase, NF-kβ = nuclear factor- kβ, P450 = cytochrome P450, PGs = prostaglandins, PLA = phospholipase A, PPAR-γ = peroxisome proliferator-activated receptor-γ, VCAM-1 = vascular cell adhesion molecule-1.

References

    1. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs) Prostaglandins Other Lipid Mediat. 2007;82:42–49. - PMC - PubMed
    1. Fretland AJ, Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chemico-Biological Interactions. 2000;129:41–59. - PubMed
    1. Sandberg M, Meijer J. Structural characterization of the human soluble epoxide hydrolase gene (EPHX2) Biochem Biophys Res Commun. 1996;221:333–339. - PubMed
    1. Larsson C, White I, Johansson C, Stark A, Meijer J. Localization of the human soluble epoxide hydrolase gene (EPHX2) to chromosomal region 8p21-p12. Hum Genet. 1995;95:356–358. - PubMed
    1. Cronin A, Mowbray S, Durk H, Homburg S, Fleming I, Fisslthaler B, Oesch F, Arand M. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc Natl Acad Sci U S A. 2003;100:1552–1557. - PMC - PubMed

LinkOut - more resources